U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07410494) titled 'Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors' on Feb. 08.
Brief Summary: This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Cancer
Breast Cancer
Non-Small Ce...